Targeting muscular microRNAs could represent a valuable strategy aimed at restoring the molecular pathways improving motor performance and enhancing the production of growth factors (such as FGFBP1) able to facilitate the re-innervation process and delay ALS progression. This evidence concerns the gene FGFBP1 and amyotrophic lateral sclerosis.